Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: smh who wrote (28270)	2/18/1999 10:39:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< There is absolutely no excuse for the lack of clarity in this release. >> I agree. Robinson needs to come out with a better press release. Targretin rights were returned to Ligand along with LGD1268 and LGD1324. Lilly and Ligand were then going to go ahead with second generation RXR agonists. I thought that LGD1268 and LGD1324 WERE the second generation RXR agonists in the LGND/LLY deal!? If so, then what compounds are they going forward with? << The characterization of the release as "vague" is charitable. >> Henry had said today that "At H&Q Robinson indicate that more progress has been made under the LLY alliances than all earlier alliances." It really would be great to find out what Robinson meant by this statement. At the rate of LGND's stock fall lately, I don't think that we shareholders can take much more "progress" in the LLY alliances! <g>

To: smh who wrote (28270)	2/18/1999 11:12:00 PM
From: smh	Respond to of 32384

A PUBLIC MESSAGE TO ANYONE AT LIGAND WHO IS PAYING ATTENTION I find today's press release difficult to fully understand. A review of the thread will indicate that I am not alone. The same review will provide the specific issues raised. Please consider the following suggestions (all of which assume ambiguity was not your intent); 1. Issue a new press release to clarify today's. 2. Provide me with a private message, addressing the questions raised on this thread today, which I can then post. 3. Ask yourself why your shareholders can't understand your press release. 4. Make sure the next release accomplishes its mission. 5. Send me an official Ligand decoder ring and I will stop giving you a hard time. SMH